I 

118TH CONGRESS 

1ST SESSION H. R. 1350 

To amend the Internal Revenue Code of 1986 to restore the amount of 

the orphan drug tax credit, and for other purposes. 

IN THE HOUSE OF REPRESENTATIVES 

MARCH 3, 2023 

Mr. GOTTHEIMER (for himself and Mr. BACON) introduced the following bill; 

which was referred to the Committee on Ways and Means, and in addition to the Committee on Energy and Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of 

such provisions as fall within the jurisdiction of the committee concerned 

A BILL 

To amend the Internal Revenue Code of 1986 to restore 

the amount of the orphan drug tax credit, and for other 

purposes. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. SHORT TITLE. 

4 This Act may be cited as ‘‘Cameron’s Law’’. 


kjohnson on DSK79L0C42PROD with BILLS
2 

•HR 1350 IH

1 SEC. 2. RESTORATION OF AMOUNT OF ORPHAN DRUG TAX 

2 CREDIT. 

3 (a) IN GENERAL.—Section 45C(a) of the Internal 

4 Revenue Code of 1986 is amended by striking ‘‘25 per5 cent’’ and inserting ‘‘50 percent’’. 

6 (b) EFFECTIVE DATE.—The amendment made by 

7 this section shall apply to taxable years beginning after 

8 the date of the enactment of this Act. 

9 SEC. 3. CDC FEASIBILITY STUDY ON SURVEILLANCE INFRA10 STRUCTURE FOR RARE DISEASES AND CON11 DITIONS. 

12 (a) STUDY.—Not later than 1 year after the date of 

13 enactment of this Act, the Director of the Centers for Dis14 ease Control and Prevention (in this section referred to 

15 as the ‘‘Director’’) shall complete a study to evaluate the 

16 feasibility of enhancing and expanding the infrastructure 

17 to track the epidemiology of rare diseases and conditions, 

18 including with respect to the following: 

19 (1) Rates of mortality. 

20 (2) Potential for research and treatment. 

21 (3) Demographics. 

22 (4) Diagnosis and progression markers. 

23 (5) The history of the disease or condition. 

24 (6) Detection management. 


kjohnson on DSK79L0C42PROD with BILLS
3 

•HR 1350 IH

1 (b) CONSULTATION.—In conducting the study re2 quired by subsection (a), the Director shall consult with 

3 relevant experts, including— 

4 (1) epidemiologists with experience in disease 

5 surveillance; 

6 (2) representatives of national voluntary health 

7 associations; 

8 (3) health information technology experts or 

9 other information management specialists; 

10 (4) clinicians with expertise in rare diseases or 

11 conditions; 

12 (5) research scientists with expertise in rare 

13 diseases or conditions, or experience conducting 

14 translational research or utilizing surveillance sys15 tems for scientific research purposes; and 

16 (6) patients, and caregivers of patients, with 

17 rare diseases or conditions. 

18 (c) REPORT.—Not later than 3 months after com19 pleting the study required by subsection (a), the Director 

20 shall submit a report to the Congress on the results of 

21 the study. 

22 (d) DEFINITION.—In this section, the terms ‘‘rare 

23 diseases and conditions’’ and ‘‘rare diseases or conditions’’ 

24 refer to human diseases and conditions that are— 


kjohnson on DSK79L0C42PROD with BILLS
4 

•HR 1350 IH

1 (1) a rare disease or condition, as defined in 

2 section 526 of the Federal Food, Drug, and Cos3 metic Act (21 U.S.C. 360bb); or 

4 (2) determined by the Director to be rare and 

5 lacking in treatment options, so as to warrant con6 sideration in the study required by subsection (a). 

Æ 


kjohnson on DSK79L0C42PROD with BILLS